Tag: advertising psychiatric drugs
An FDA Whistleblower’s Documents: Commerce, Corruption, and Death
In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.
The Perils of Direct-to-Consumer Advertising
The job of educating the public on common medical conditions and the range, efficacy, benefits, and risks of potential treatment options should be undertaken by an independent and objective government health agency, not a for-profit, multi-billion dollar industry with a conflict of interest.
“Direct-to-Consumer Advertising — Selling Drugs or Diseases?”
With the American Medical Association (AMA) declaring its opposition to direct-to-consumer (DTC) drug advertising, Martha Rosenberg asks, did DTC increase the number of people who have "diseases"?
